Vero

Provectus Biopharmaceuticals Provides Update on Research into Oral Administration of PV-10® Immunotherapy for Treatments of Hematology, Oncology, and Virology

Retrieved on: 
Monday, October 4, 2021
Patent, Mouse, OTCQB, National, Method, Hematology, Severe acute respiratory syndrome coronavirus 2, CT, Oral administration, Immunogenic cell death, Cancer, Virology, Patient, Rhabdomyosarcoma, Microbiology, USPTO, Neuroblastoma, Adult, Immune system, GLOBE, Immunotherapy, Company, Legislation, Ophthalmology, Liver, Cell proliferation, Oral, Ewing's sarcoma, Research, Calu-3, Dermatology, NIH, Survival, Safety, Forward-looking statement, Acute lymphoblastic leukemia, Osteosarcoma, Vero, Skin, Medical imaging, Ridesharing company, Pharmaceutical industry, Vaccine

Hematology: On August 5, 2021, the U.S. Patent and Trademark Office (USPTO) published Provectus patent application entitled Composition and Method for Oral Treatment of Leukemia ( publication no.

Key Points: 
  • Hematology: On August 5, 2021, the U.S. Patent and Trademark Office (USPTO) published Provectus patent application entitled Composition and Method for Oral Treatment of Leukemia ( publication no.
  • US 2021/0236418 A1 ), containing:
    In vivo data of mice with acute lymphoblastic leukemia that received oral PV-10 and displayed increased survival.
  • Provectus expects these and other related data from the hematology program to be published in a peer-reviewed medical journal in 2022.
  • Provectus expects that data from the oncology and virology programs would be published when appropriate.

Valneva Continues Expansion of Clinical Trials of its Inactivated COVID-19 Vaccine Candidate VLA2001

Retrieved on: 
Thursday, September 23, 2021
Infection, Vaccine, Euronext Paris, University Hospital Southampton NHS Foundation Trust, Volunteering, 1018, Saint-Herblain, Adolescence, Chikungunya, Profile, Royal commission, VLA, Company, Lyme disease, Vaccination, COVID-19, Technology, Severe acute respiratory syndrome coronavirus 2, European Commission, CpG, Nasdaq, Vero, EMA, United Kingdom, Pharmaceutical industry

This planned expansion of VLA2001 clinical trials will support future approval in further age groups, in addition to adults.

Key Points: 
  • This planned expansion of VLA2001 clinical trials will support future approval in further age groups, in addition to adults.
  • Valneva is conducting several clinical trials of VLA2001.
  • VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 Vaccine

Retrieved on: 
Tuesday, September 14, 2021
European Medicines Agency, CpG, Vaccination, Technology, 2020 European Medicines Agency cyberattack, 1018, Company, Nasdaq, EMA, Chikungunya, Safety, Infection, Saint-Herblain, Vaccine, Severe acute respiratory syndrome coronavirus 2, MHRA, Vero, Lyme disease, United Kingdom, COVID-19, Volunteering, Time, Health care, Pharmaceutical industry

Saint-Herblain (France), September 14, 2021 Valneva SE , a specialty vaccine company, today announced that it has completed recruitment of the initial cohort of elderly participants in Valnevas Phase 3 trial, VLA2001-304, of its inactivated COVID-19 vaccine candidate, VLA2001.

Key Points: 
  • Saint-Herblain (France), September 14, 2021 Valneva SE , a specialty vaccine company, today announced that it has completed recruitment of the initial cohort of elderly participants in Valnevas Phase 3 trial, VLA2001-304, of its inactivated COVID-19 vaccine candidate, VLA2001.
  • We believe that our differentiated vaccine candidate can make a major contribution to the ongoing fight against the COVID-19 pandemic.
  • VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe.
  • VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.

Valneva Receives Notice of Termination of COVID-19 Vaccine Supply Agreement by UK Government

Retrieved on: 
Monday, September 13, 2021

Saint-Herblain (France), September 13, 2021 Valneva SE , a specialty vaccine company, today announced that it has received a termination notice from the UK Government (HMG) in relation to the Supply Agreement for its COVID-19 vaccine candidate, VLA2001.

Key Points: 
  • Saint-Herblain (France), September 13, 2021 Valneva SE , a specialty vaccine company, today announced that it has received a termination notice from the UK Government (HMG) in relation to the Supply Agreement for its COVID-19 vaccine candidate, VLA2001.
  • HMG has alleged that the Company is in breach of its obligations under the Supply Agreement, but the Company strenuously denies this.
  • Subject to these data and MHRA approval, Valneva believes that initial approval for VLA2001 could be granted in late 2021.
  • It then applies its deep understanding of vaccine science, including its expertise across multiple vaccine modalities, as well as its established vaccine development capabilities, to develop prophylactic vaccines to address these diseases.

Total Testing Solutions Partners with Vero Diagnostics Lab to Provide Ultra-Rapid Covid-19 PCR Tests

Retrieved on: 
Thursday, September 9, 2021

LOS ANGELES, Sept. 9, 2021 /PRNewswire/ -- Total Testing Solutions (TTS) announced today they are partnering with state-of-the-art laboratory, Vero Diagnostics to bring Vero's highly complex lab testing to their Los Angeles testing centers.

Key Points: 
  • LOS ANGELES, Sept. 9, 2021 /PRNewswire/ -- Total Testing Solutions (TTS) announced today they are partnering with state-of-the-art laboratory, Vero Diagnostics to bring Vero's highly complex lab testing to their Los Angeles testing centers.
  • These tests are the fastest PCR testing available on the market, providing results in as little as 30 minutes.
  • TTS will continueto have quick turnaround testing (24-48hrs) available for freeat all of their testing sites; however, the super expedited PCR testing through Vero Diagnostics will be available only at their Century City & North Hollywood locations.
  • "We are thrilled to be partnering with Vero to utilize their cutting-edge technology in our testing centers.

Orchid Insurance VP Named HR Florida State Council Professional of the Year

Retrieved on: 
Wednesday, September 8, 2021
Professional Services, Insurance, Finance

Orchid Underwriters Agency, LLC, (Orchid Insurance), among the largest independent managing general underwriters in the United States, announced today that Jehane Myers, Vice President of Human Resources, has been named HR Professional of the Year by the HR Florida State Council.

Key Points: 
  • Orchid Underwriters Agency, LLC, (Orchid Insurance), among the largest independent managing general underwriters in the United States, announced today that Jehane Myers, Vice President of Human Resources, has been named HR Professional of the Year by the HR Florida State Council.
  • View the full release here: https://www.businesswire.com/news/home/20210908006036/en/
    Jehane Myers, Vice President of Human Resources, has been named HR Professional of the Year by the HR Florida State Council.
  • Employees are at the heart of everything Jehane does, said Kathy Cody, President and Chief Operating Officer at Orchid Insurance.
  • Representing more than 16,000 individual human resource professionals, the HR Florida State Council is the state affiliate for the Society for Human Resource Management (SHRM).

Valneva Commences Rolling Submission to MHRA for its Inactivated, Adjuvanted COVID-19 Vaccine

Retrieved on: 
Monday, August 23, 2021
Public Health England, Company, Valneva SE, Government, Health care, EMA, COVID-19 vaccine, Infection, Severe acute respiratory syndrome coronavirus 2, UK Government Decontamination Service, Technology, 1018, Lyme disease, Nasdaq, PHE, NIHR, Clinical trial, VLA, National Institute for Health Research, CpG, United Kingdom, VLA2001, Euronext Paris, Vaccine, MHRA, Vero, Vaccination, Chikungunya, COVID-19, Saint-Herblain, National Institute, Medication, Pharmaceutical industry

VLA2001 is a whole virus, inactivated, adjuvanted vaccine candidate and is the only vaccine candidate of this type currently in clinical trials in Europe.

Key Points: 
  • VLA2001 is a whole virus, inactivated, adjuvanted vaccine candidate and is the only vaccine candidate of this type currently in clinical trials in Europe.
  • Subject to positive Cov-Compare data and MHRA review, Valneva believes that initial approval could be granted before the end of 2021.
  • Juan Carlos Jaramillo M.D., Chief Medical Officer of Valneva, said, We are pleased to begin the regulatory review process for our COVID-19 vaccine with the MHRA.
  • VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.

Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate

Retrieved on: 
Wednesday, August 11, 2021
Cohort, VLA, Euronext Paris, Safety, Immunization, Company, Vero, Ageing, CpG, Technology, Vaccine, 1018, Volunteering, Profile, COVID-19, Valneva SE, Vaccination, EMA, Severe acute respiratory syndrome coronavirus 2, Infection, Nasdaq, Population, Lyme disease, Chikungunya, Saint-Herblain

Hence we are extremely pleased to be able to invest in this very important additional clinical trial.

Key Points: 
  • Hence we are extremely pleased to be able to invest in this very important additional clinical trial.
  • In June 2021, Valneva announced that it had completed recruitment for VLA2001s pivotal Phase 3 trial Cov-Compare (VLA2001-301) with over 4,000 randomized participants.
  • VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.
  • It then applies its deep understanding of vaccine science, including its expertise across multiple vaccine modalities, as well as its established vaccine development capabilities, to develop prophylactic vaccines to address these diseases.